Cell Therapy CDMO Market

Cell Therapy CDMO Market Research, 2034

Cell Therapy CDMO Market is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 22.7% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 5.9 billion and is projected to reach USD 55.8 billion by the completion of 2034.

Cell Therapy CDMO stands for Contract Development and Manufacturing Organization and offers services for the development and manufacturing of cell-based therapies. These treatments use living cells to cure or stop illnesses. CDMOs provide various services such as the development of operations, producing clinical trial materials, and manufacturing for commercial purposes. In addition, they are important for transforming laboratory findings into clinical products, thus ensuring scalability, quality control, and regulatory compliance. This collaboration allows biotech and pharmaceutical firms to focus on innovation and exploration by using the production and logistics proficiency of CDMOs to accelerate the development and accessibility of advanced cell therapies.

Market Highlights

Cell Therapy CDMO Market is expected to grow at a compound annual growth rate (CAGR) of 22.7% from 2024 to 2034

Cell Therapy CDMO Market is projected to reach USD 55.8 billion over the forecast period, due to an increase in the demand for cell-based therapies for cancer, genetic disorders, and chronic diseases. The growth in the market is attributed to the progress in biotechnology, along with high investments and a positive regulatory ecosystem. Additionally, major stakeholders are forming strategic partnerships, making acquisitions, and implementing technological developments to improve their capabilities. Moreover, several factors are driving this positive trend, such as an increase in clinical trials and the demand for GMP-compliant manufacturing solutions. Besides, the competitive atmosphere in the market includes well-known companies and upcoming market players who are working to address the demand for advanced cell therapy production services.

Cell Therapy CDMO Market Segmentation

Stem Cell segment will lead the industry due to its importance in treating chronic illnesses

Cell Therapy CDMO Market is divided by Type into Stem Cell and Non-Stem Cell. The Stem Cell segment is at the forefront of the Cell Therapy CDMO market due to the immense healing capabilities of stem cells in the treatment of various diseases like cancers, heart issues, and neurological disorders. Stem cells have special regenerative abilities, which make them very adaptable and important for creating new treatments. Furthermore, innovations in stem cell studies and a rise in clinical trials have boosted the need for products that use stem cells. Thus, the significance of stem cells in the Cell Therapy CDMO market is strengthened by their scalability and the ability to address conditions that were previously difficult to treat.

Commercial segment will dominate the market due to multiple cell-based therapies shifting to clinical trials.

Cell Therapy CDMO Market is segmented by Application into Commercial and Academic Research. The Cell Therapy CDMO market is led by the commercial segment, owing to the high number of cell-based therapies moving to later stages of clinical trials and obtaining regulatory green lights. This sector is being supported by major funding from pharmaceutical and biotech firms that are dedicated to creating and selling modern treatments. The increasing need for manufacturing and strong quality control motivates CDMOs to focus more on serving commercial uses. Moreover, the growth of the commercial segment is improved due to strategic partnerships and collaborations with biotech companies. On the contrary, academic research plays an important role in early-stage discoveries and innovation but usually does not need as much scale or regulatory strictness as commercial production.

Market Dynamics

Growth Drivers

Advancements in Biotechnology to Drive Growth in the Cell Therapy CDMO Market

Cell Therapy CDMO market is experiencing major expansion due to recent developments in biotechnology. Innovations like CRISPR-Cas9 gene editing, better methods for growing stem cells, and discoveries in regenerative medicine are driving the development of modern cell-based treatments. These developments allow for more accurate and personalized treatment choices for various illnesses like cancer, genetic disorders, and degenerative ailments. Additionally, with the growth of biotechnological methods, the complexity of cell therapy production also increases and requires special CDMO services. Thus, CDMOs offer the necessary skills and facilities to transform new technologies into medically effective products and speed up the growth of modern cell therapies.

High Investment Act as a Catalyst for Market Growth

Substantial growth in the cell therapy CDMO market is due to high investment from pharmaceutical companies and venture capitalists. This increase in funding is motivated by the promising possibilities of cell-based therapies for the treatment of various complex diseases. Moreover, financial support helps in research and development efforts, along with conducting clinical trials and bringing new therapies to market. Furthermore, investors are drawn to the promising market potential that successful cell therapies can bring. This funding allows CDMOs to improve their skills and adopt new technologies, thus ensuring they can meet the high demand for advanced cell therapy manufacturing services.

Restraints

Regulatory Challenges in the Cell Therapy CDMO Market Will Impact the Growth

Regulatory challenges are a major limitation for the Cell Therapy CDMO market. Navigating regulatory structures set by agencies like the FDA and EMA is crucial for the development and commercialization of cell-based therapies. These rules ensure the safety of patients and the efficiency of products, but they also present challenges in meeting requirements and expenses. Moreover, lengthy clinical data and adherence to good manufacturing practices may cause delays in the development of products and raise costs. Besides, the changing regulations in the biotechnology field further add to the complexity and present difficulties for CDMOs and their partners in launching new therapies.

Recent Developments

• In March 2023, Lonza announced the expansion of its cell and gene therapy manufacturing facility in Houston, USA, to increase production capacity and capabilities.
• In January 2023, WuXi AppTec expanded its cell and gene therapy testing capabilities at its facility in Philadelphia, USA, to support the growing demand for advanced therapies.
• In October 2023, Thermo Fisher Scientific acquired viral vector manufacturer, Brammer Bio, to enhance its cell and gene therapy manufacturing capabilities.
• In September 2023, Catalent announced the opening of a new state-of-the-art cell therapy manufacturing facility in Gosselies, Belgium, to support clinical and commercial production.
• In February 2023, Samsung Biologics entered into a strategic partnership with Biogen to accelerate the production of biosimilars and advanced cell therapies​.

Key Players:

• Lonza Group
• WuXi AppTec
• Thermo Fisher Scientific
• Catalent Inc.
• Charles River Laboratories
• Samsung Biologics
• FUJIFILM Diosynth Biotechnologies
• Cobra Biologics
• BioNTech IMFS
• CCRM
• PCT
• Apceth Biopharma
• Brammer Bio
• Novartis AG
• Parexel International Corporation
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)

Regional Analysis

Cell Therapy CDMO Market is segmented based on regional analysis into five key regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. The North American region will lead the Cell Therapy CDMO market as the region has a strong biotechnology network with advanced research and development capabilities, along with large investments in advanced treatments. In addition, regulatory frameworks are strict but clearly defined in the region, thus assisting businesses as they navigate the approval process. Besides, the presence of major pharmaceutical companies and small biotech companies promotes cooperation and accelerates the expansion of the market.

In the coming years, the Asia-Pacific region is expected to demonstrate impressive performance. This expectation is due to the growth of healthcare facilities, huge funding in biotechnology, and the rising use of advanced treatments in countries such as China, Japan, and South Korea. These countries are working on improving their manufacturing capacities and regulatory systems to attract international investments and create a favorable environment for the development of the Cell Therapy CDMO market.

Cell Therapy CDMO Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Cell Therapy CDMO Market Scope and Segments:

Frequently Asked Questions (FAQ):